Johnson & Johnson has hired Emergent BioSolutions as a US manufacturing partner for its lead COVID-19 vaccine candidate Under the pact, worth about $135 million, Emergent will make the vaccine’s active ingredient starting later this year at its facility in Baltimore J&J also signed a deal to use capacity at Catalent’s biologic drug facility in Bloomington, Indiana J&J has a plan to produce 1 billion doses of its adenovirus-based vaccine View: PDF ;Full Text HTML